Loading...
OTCM
PARD
Market cap0kUSD
Jun 23, Last price  
0.00USD
Name

Poniard Pharmaceuticals Inc

Chart & Performance

D1W1MN
OTCM:PARD chart
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0k
400,0009,200,0003,700,0001,600,000300,0004,800,00010,400,0009,100,000600,0003,549,0002,873,00011,054,00010,531,0001,015,00015,00000000
Net income
-30m
L-34.26%
-11,700,000-2,800,000-8,500,000-11,100,000-12,300,000-9,000,000-2,600,000-4,400,000-12,000,000-11,402,000-23,802,000-23,093,000-5,059,000-19,371,000-20,997,000-23,294,000-32,782,000-48,565,000-45,715,000-30,051,000
CFO
-24m
L-31.60%
-9,300,000-5,800,000-8,100,000-10,300,000-10,000,000-7,900,000-2,900,000-3,400,000-10,800,000-17,038,000-18,511,000-15,409,000-4,066,000-17,480,000-16,467,000-17,274,000-24,653,000-33,487,000-35,491,000-24,276,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the discovery and market introduction of cancer treatments. Its flagship product candidate, Picoplatin, is a platinum-based therapy targeting various cancer types, such as small cell lung, colorectal, prostate, and ovarian cancers. The company has advanced Picoplatin through several clinical stages, including a pivotal Phase III SPEAR trial for small cell lung cancer patients in a second-line treatment setting. Furthermore, Phase II studies investigated Picoplatin as an initial therapy for metastatic colorectal cancer and hormone-refractory prostate cancer. An early-stage Phase I trial also examined an oral formulation of Picoplatin for solid tumors. Founded in 1984 as NeoRx Corporation, the company rebranded to Poniard Pharmaceuticals, Inc. in September 2006 and operates from its base in Seattle, Washington.
URL
poniard.com
IPO date
Dec 30, 2011
Employees
7
Domiciled in
US
Incorporated in
US

Valuation

No data to show